tiprankstipranks

Finch Therapeutics Group to Delist from Nasdaq

Protect Your Portfolio Against Market Uncertainty

The latest update is out from Finch Therapeutics Group ( (FNCH) ).

Finch Therapeutics Group has announced plans to delist its common stock from the Nasdaq and deregister it under the Securities Exchange Act, aiming to cut costs associated with SEC reporting and compliance with Nasdaq standards. The stock, previously suspended by Nasdaq, has been trading on the OTC Markets and is expected to continue there post-delisting. The company believes this move best serves its interests and those of its shareholders, although no guarantees are made about future trading on the OTC.

Find detailed analytics on FNCH stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App